Skip to main content

Table 3 Clinical outcomes of patients according to the timing of endoscopy from IDC onset

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic Endoscopy > 30 days of onset
N = 40
Endoscopy ≤ 30 days of onset
N = 142
P value Endoscopy > 7 days of onset
N = 89
Endoscopy ≤ 7 days of onset
N = 93
P value
IV steroids, n (%) 23 (57.5) 60 (42.3) 0.054 46 (66.7) 37 (56.9) 0.287
Duration of symptoms (days, SD) 54 (92) 26 (77) 0.062 47 (104) 19 (47) 0.026
Duration of steroid (days, SD) 87 (120) 53 (41) 0.019 74 (90) 49 (43) 0.053
Infliximab/vedolizumab, n (%) 8 (22.9) 34 (32.1) 0.395 26 (29.2) 27 (29.0) 1.000
Duration from onset to first infliximab/vedolizumab dose (days, SD) 31 (23) 15 (14) 0.030 23 (17) 14 (17) 0.154
Colonoscopy findings, n (%)    0.161    0.263
 Ulcer 9 (22.5) 40 (28.2)   27 (30.3) 22 (23.7)  
 Non-ulcerative inflammation 11 (27.5) 55 (38.7)   27 (30.3) 39,941.9)  
 Normal 20 (50.0) 47 (33.1)   35 (39.3) 32 (34.4)  
High-risk endoscopic features, n (%) 14 (35.0) 57 (40.1) 0.587 37 (41.6) 34 (36.6) 0.544
Active histological inflammation, n (%) 29 (72.5) 100 (70.4) 0.847 63 (70.8) 66 (71.0) 1.000
Outcomes, n (%)
 Hospitalization 27 (67.5) 105 (73.9) 0.428 58 (65.2) 74 (79.6) 0.032
 Duration of hospitalization (days, SD) 9 (7) 7 (6) 0.138 9 (7) 6 (7) 0.068
 ICU admission 4 (10) 3 (2.1) 0.072 4 (4.5) 3 (3.2) 0.856
 Recurrence 20 (50.0) 31 (21.8) 0.001 60 (67.4) 71 (76.3) 0.191
  1. Abbreviation: ICU intensive care unit, IV intravenous, SD standard deviation